InflaRx (IFRX) Cash & Equivalents (2016 - 2026)

InflaRx has reported Cash & Equivalents for 11 years, with the latest figure at $17.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 64.71% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (down 64.71% YoY) and the FY2025 annual result came in at $18.1 million, down 9.1% from the prior year.
• Cash & Equivalents fell to $17.6 million in Q1 2026 per IFRX's latest filing, from $18.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $49.7 million in Q1 2025 and troughed at $2.3 million in Q1 2023.
• A 5-year average of $21.3 million and a median of $18.7 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 95.0% in 2023, then surged 1111.47% in 2024.
• Over 5 years, Cash & Equivalents stood at $16.6 million in 2022, then retreated by 17.22% to $13.7 million in 2023, then jumped by 43.13% to $19.7 million in 2024, then declined by 5.15% to $18.7 million in 2025, then fell by 5.88% to $17.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $17.6 million, $18.7 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.